(Q37710377)

22 August 2017

1 reference

title

Aldosterone: effects on the kidney and cardiovascular system (English)

1 reference

22 August 2017

1 reference

Marie Briet

1

1 reference

22 August 2017

Ernesto L Schiffrin

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

16 March 2010

1 reference

Nature Reviews Nephrology

22 August 2017

published in

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

261-273

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.30

22 August 2017

exact match

0 references

cites work

Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence: a possible new mechanism for glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone-induced inflammation in the rat heart : role of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone induces a vascular inflammatory phenotype in the rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Shape-engineered vascular endothelial cells: nitric oxide production, cell elasticity, and actin cytoskeletal features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

The kidney-specific WNK1 isoform is induced by aldosterone and stimulates epithelial sodium channel-mediated Na+ transport

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Role of aldosterone in the remnant kidney model in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Mineralocorticoids, hypertension, and cardiac fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Regression of existing glomerulosclerosis by inhibition of aldosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Spironolactone improves angiotensin-induced vascular changes and oxidative stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Effect of aldosterone on renal transforming growth factor-beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Development of Rho-kinase inhibitors for cardiovascular medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Albuminuria in chronic heart failure: prevalence and prognostic importance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Extended prognostic value of urinary albumin excretion for cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Strict blood-pressure control and progression of renal failure in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Beneficial impact of spironolactone in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Targeting proteinuria as a valid surrogate for individualized kidney protective therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Vascular hypertrophy and remodeling in secondary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone induces superoxide generation via Rac1 activation in endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

NOX2 and NOX4 mediate proliferative response in endothelial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone activates endothelial exocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Effect of aldosterone on vascular angiotensin II receptors in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Mineralocorticoid receptor antagonism in experimental atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Human endothelium: target for aldosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Plasma sodium stiffens vascular endothelium and reduces nitric oxide release.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone induces contraction of the resistance arteries in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Rapid nongenomic effects of aldosterone on human forearm vasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Nongenomic vascular action of aldosterone in the glomerular microcirculation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.30

Mineralocorticoid excess, dietary sodium, and myocardial fibrosis

31 March 2020

1 reference

12 December 2020

Short term cardiovascular effects of aldosterone in healthy male volunteers

1 reference

12 December 2020

Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells

1 reference

12 December 2020

Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN)

1 reference

12 December 2020

Reconsidering the roles of the mineralocorticoid receptor

1 reference

12 December 2020

Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats

1 reference

12 December 2020

Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2010.30

1 reference

22 August 2017

1 reference